182 related articles for article (PubMed ID: 32227579)
1. A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.
Feng X; Tang R; Zhang R; Wang H; Ji Z; Shao Y; Wang S; Zhong T; Gu Y; Meng J
J Cell Mol Med; 2020 May; 24(9):5238-5248. PubMed ID: 32227579
[TBL] [Abstract][Full Text] [Related]
2. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
3. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of TET2 in Female Cancers.
Wan F; Chen F; Fan Y; Chen D
Front Bioeng Biotechnol; 2022; 10():790605. PubMed ID: 35223782
[TBL] [Abstract][Full Text] [Related]
5. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
Anurag M; Zhu M; Huang C; Vasaikar S; Wang J; Hoog J; Burugu S; Gao D; Suman V; Zhang XH; Zhang B; Nielsen T; Ellis MJ
J Natl Cancer Inst; 2020 Jul; 112(7):737-746. PubMed ID: 31665365
[TBL] [Abstract][Full Text] [Related]
8. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
10. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.
Carvajal-Hausdorf DE; Mani N; Velcheti V; Schalper KA; Rimm DL
J Immunother Cancer; 2017 Oct; 5(1):81. PubMed ID: 29037255
[TBL] [Abstract][Full Text] [Related]
11. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Hennequart M; Pilotte L; Cane S; Hoffmann D; Stroobant V; Plaen E; Van den Eynde BJ
Cancer Immunol Res; 2017 Aug; 5(8):695-709. PubMed ID: 28765120
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
13. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer.
Liu X; Yan G; Xu B; Yu H; An Y; Sun M
Front Immunol; 2022; 13():1006501. PubMed ID: 36248886
[TBL] [Abstract][Full Text] [Related]
15. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
Zhai L; Ladomersky E; Lauing KL; Wu M; Genet M; Gritsina G; Győrffy B; Brastianos PK; Binder DC; Sosman JA; Giles FJ; James CD; Horbinski C; Stupp R; Wainwright DA
Clin Cancer Res; 2017 Nov; 23(21):6650-6660. PubMed ID: 28751450
[No Abstract] [Full Text] [Related]
16. IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma.
Struckmeier AK; Radermacher A; Fehrenz M; Bellin T; Alansary D; Wartenberg P; Boehm U; Wagner M; Scheller A; Hess J; Moratin J; Freudlsperger C; Hoffmann J; Thurner L; Roemer K; Freier K; Horn D
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3623-3635. PubMed ID: 35963900
[TBL] [Abstract][Full Text] [Related]
17. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the novel omicron receptor AXL in cancers.
Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
[TBL] [Abstract][Full Text] [Related]
19. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
[TBL] [Abstract][Full Text] [Related]
20. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
Jacquemier J; Bertucci F; Finetti P; Esterni B; Charafe-Jauffret E; Thibult ML; Houvenaeghel G; Van den Eynde B; Birnbaum D; Olive D; Xerri L
Int J Cancer; 2012 Jan; 130(1):96-104. PubMed ID: 21328335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
